Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: The NOA-08 randomised, phase 3 trial

摘要

Because the current median age of glioblastoma diagnosis is about 65 years, approximately one-half of glioblastoma patients may be defined as elderly (2). The number of these patients is expected to markedly rise as the population ages. Advanced age is intrinsically tied to increasing number of medical comorbidities and overall decrease in physical resilience. Treatment tolerance, efficacy, and quality of life are thus affected by aggressive cancer therapies. Consequently, investigations exploring aggressive treatments have understandably limited their subject eligibility to younger patients with superior performance status (3, 4).